Goodwin Advises Duality Biologics to Enter Exclusive Option Agreement With GSK for a Novel Antibody-Drug Conjugate for Up to $975 Million
December 18, 2024
December 18, 2024
BOSTON, Massachusetts, Dec. 18 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Duality Biologics to enter into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324. Under the agreement, DualityBio will grant GSK an exclusive option to obtain a license to develop and commercialize DB-1324 worldwide (excluding mainland China, Hong Kong, and Macau) (the "Option"). Under the terms of the agreeme . . .
The Life Sciences team advised Duality Biologics to enter into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324. Under the agreement, DualityBio will grant GSK an exclusive option to obtain a license to develop and commercialize DB-1324 worldwide (excluding mainland China, Hong Kong, and Macau) (the "Option"). Under the terms of the agreeme . . .